{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:54:38Z","timestamp":1791125678563,"version":"4.1.0"},"reference-count":56,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,4,12]],"date-time":"2010-04-12T00:00:00Z","timestamp":1271030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Glucocorticoids are an integral component of therapy for acute lymphoblastic leukaemia (ALL), but usage differs between cooperative group protocols. All groups use glucocorticoids during induction but vary on whether to use dexamethasone or prednisone. Issues to consider in the choice of induction steroid include impact on event\u2010free and overall survival, acute morbidity such as infection risk, diabetes, and behavioural disturbances and long\u2010term complications such as avascular necrosis. It is generally agreed that dexamethasone is the steroid of choice for groups using a delayed intensification phase, but dosing schedules (intermittent <jats:italic>versus<\/jats:italic> continuous) vary. There is no consensus on the potential benefit of steroid administration during maintenance therapy. This review will summarize the current available data on steroid use in paediatric ALL, highlighting outcomes as well as major toxicities.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2010.08192.x","type":"journal-article","created":{"date-parts":[[2010,4,12]],"date-time":"2010-04-12T10:36:09Z","timestamp":1271068569000},"page":"638-652","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers"],"prefix":"10.1111","volume":"149","author":[{"given":"Jennifer L.","family":"McNeer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Nachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,5,17]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"747","article-title":"Osteonecrosis: an emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia","volume":"88","author":"Arico M.","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/sarh.2002.33724b"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.2.202"},{"key":"e_1_2_7_5_1","first-page":"8","article-title":"Dexamethasone (DEX)(6mg\/sm\/d) and prednisolone (PRED)(60mg\/sm\/d) in induction therapy of childhood ALL are equally effective: results of the 2nd interim analysis of EORTC trial 58951","volume":"112","author":"Bertrand Y.","year":"2008","journal-title":"Blood (ASH Meeting Abstracts)"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.6.1012"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-132837"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2454"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20244"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91615-3"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60073-7"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-248146"},{"key":"e_1_2_7_13_1","first-page":"11","article-title":"Improved outcome with pulses of vincristine and steroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and non hodgkin lymphoma (NHL): final report of the EORTC randomised phase III trial 58951","volume":"112","author":"De Moerloose B.","year":"2008","journal-title":"Blood (ASH Meeting Abstracts)"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199502000-00001"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-198821000-00009"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.11.2234"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401939"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1034450"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000415)88:8<1964::AID-CNCR27>3.0.CO;2-1"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.009"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.982"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.8.2370"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950190411"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-186502"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199608)27:2<114::AID-MPO8>3.0.CO;2-I"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2009.02.007"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.825"},{"key":"e_1_2_7_28_1","first-page":"9","article-title":"Escalating dose intravenous methotrexate without leucovorin rescue during interim maintenance is superior to oral methotrexate for children with standard risk acute lymphoblastic leukemia (SR\u2010ALL): Children\u2019s Oncology Group study 1991","volume":"112","author":"Matloub Y.","year":"2008","journal-title":"Blood (ASH Meeting Abstracts)"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.18.3262"},{"key":"e_1_2_7_30_1","first-page":"898","article-title":"Increased incidence of osteonecrosis (ON) with a dexamethasone (DEX) induction for high risk acute lymphoblastic leukemia (HR\u2010ALL): a report from the Children\u2019s Oncology Group (COG)","volume":"112","author":"Mattano L.A.","year":"2008","journal-title":"Blood (ASH Meeting Abstracts)"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05509.x"},{"key":"e_1_2_7_32_1","first-page":"899","article-title":"No influence on the incidence of osteonecroses when dexamethasone replaces prednisone during induction treatment for childhood ALL: results of trial ALL\u2010BFM 2000","volume":"112","author":"Moricke A.","year":"2008","journal-title":"Blood (ASH Meeting Abstracts)"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.257"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080324"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.3.920"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199806043382304"},{"key":"e_1_2_7_37_1","first-page":"163","article-title":"The Norton\u2013Simon hypothesis revisited","volume":"70","author":"Norton L.","year":"1986","journal-title":"Cancer Treatment Reports"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.9.3122.3122"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.2174\/1566524033479357"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1026781"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401973"},{"key":"e_1_2_7_42_1","first-page":"7","article-title":"Dexamethasone in induction can eliminate one\u2010third of all relapses in childhood acute lymphoblastic leukemia (ALL): results of an international randomised trial in 3655 patients (trial AIEOP\u2010BFM ALL 2000)","volume":"112","author":"Schrappe M.","year":"2008","journal-title":"Blood (ASH Meeting Abstracts)"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-070342"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1211"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.12.3066"},{"key":"e_1_2_7_46_1","first-page":"178","article-title":"In vitro comparative antileukemic activity of various glucocorticoids in childhood acute leukemia","volume":"49","author":"Styczynski J.","year":"2002","journal-title":"Neoplasma"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.07.002"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.527"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.911"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70228-1"},{"key":"e_1_2_7_51_1","first-page":"910","article-title":"Incidence and outcome of osteonecrosis in children and young adults with acute lymphoblastic leukaemia treated on a dexamethasone containing protocol: results of the Medical Research Council UK trial ALL 2003","volume":"112","author":"Vora A.","year":"2008","journal-title":"Blood (ASH Meeting Abstracts)"},{"key":"e_1_2_7_52_1","first-page":"321","article-title":"Dexamethasone and individualized asparaginase dosing are each associated with superior event\u2010free survival in childhood acute lymphoblastic leukemia: results from DFCI\u2010ALL Consortium protocol 00\u201001","volume":"114","author":"Vrooman L.M.","year":"2009","journal-title":"Blood (ASH Meeting Abstracts)"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200005000-00004"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-45495"},{"key":"e_1_2_7_55_1","first-page":"583","article-title":"Delayed intensification (DI) enhances event\u2010free survival (EFS) of children with B\u2010precursor acute lymphoblastic leukemia (ALL) who received intensification therapy with six courses of intravenous methotrexate (MTX): POG 9904\/9905: a Children\u2019s Oncology Group study (COG)","volume":"110","author":"Winick N.","year":"2007","journal-title":"Blood (ASH Meeting Abstracts)"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/jor.20733"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevEukaryotGeneExpr.v13.i24.140"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2010.08192.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2010.08192.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T18:36:59Z","timestamp":1697395019000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2010.08192.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,17]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1111\/j.1365-2141.2010.08192.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08192.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,17]]},"assertion":[{"value":"2010-05-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}